Media headlines about Stryker (NYSE:SYK) have trended somewhat positive on Thursday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Stryker earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned news stories about the medical technology company an impact score of 46.4546937497155 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:
- Stryker to host conference call on April 26, 2018 (finance.yahoo.com)
- Stryker Co. (SYK) Given Average Rating of “Buy” by Analysts (americanbankingnews.com)
- Stryker announces Annual Meeting of Shareholders (finance.yahoo.com)
- BRIEF-Stryker Corp Says CEO Kevin A. Lobo’s 2017 Total Compensation Was $14 Million (feeds.reuters.com)
- Stryker wins Deal of the Year for buying Novadaq – Mergers & Acquisitions (themiddlemarket.com)
A number of equities research analysts have recently weighed in on the stock. Needham & Company LLC restated a “hold” rating on shares of Stryker in a report on Wednesday, January 17th. Robert W. Baird upgraded shares of Stryker from a “neutral” rating to an “outperform” rating in a report on Friday, November 24th. ValuEngine lowered shares of Stryker from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Royal Bank of Canada restated a “buy” rating and issued a $175.00 price objective on shares of Stryker in a report on Tuesday, January 9th. Finally, Morgan Stanley raised their price objective on shares of Stryker from $179.00 to $186.00 and gave the company an “overweight” rating in a report on Monday, February 26th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and sixteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $164.76.
Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.95 by $0.01. Stryker had a net margin of 8.20% and a return on equity of 24.56%. The company had revenue of $3.47 billion for the quarter, compared to the consensus estimate of $3.42 billion. During the same period last year, the firm posted $1.78 EPS. Stryker’s revenue for the quarter was up 9.9% on a year-over-year basis. sell-side analysts anticipate that Stryker will post 7.12 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 30th. Shareholders of record on Thursday, March 29th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 1.17%. The ex-dividend date of this dividend is Wednesday, March 28th. Stryker’s payout ratio is currently 70.15%.
In other Stryker news, Director Howard E. Cox, Jr. sold 7,400 shares of the firm’s stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $164.09, for a total transaction of $1,214,266.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP William E. Berry, Jr. sold 1,306 shares of the firm’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $164.42, for a total transaction of $214,732.52. The disclosure for this sale can be found here. Insiders have sold a total of 98,730 shares of company stock worth $16,360,442 over the last three months. 7.40% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY WARNING: “Stryker (SYK) Getting Somewhat Positive News Coverage, Analysis Finds” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3290019/stryker-syk-getting-somewhat-positive-news-coverage-analysis-finds.html.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.